HLB Life Science Co., Ltd. (067630.KQ)
KRW 6500.0
(3.17%)
KRW 6500.0
(3.17%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 97.99 Billion KRW | -1.61% |
| 2022 | 99.59 Billion KRW | 86.17% |
| 2021 | 53.49 Billion KRW | -41.73% |
| 2020 | 91.79 Billion KRW | -19.49% |
| 2019 | 114.01 Billion KRW | 11.26% |
| 2018 | 102.47 Billion KRW | -3.73% |
| 2017 | 106.44 Billion KRW | 152.03% |
| 2016 | 42.23 Billion KRW | 54.57% |
| 2015 | 27.32 Billion KRW | -25.26% |
| 2014 | 36.56 Billion KRW | 83.21% |
| 2013 | 19.95 Billion KRW | 121.79% |
| 2012 | 8.99 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 23.58 Billion KRW | -1.31% |
| 2024 Q1 | 23.89 Billion KRW | 1.46% |
| 2023 Q2 | 21.42 Billion KRW | -31.24% |
| 2023 Q4 | 23.55 Billion KRW | 7.81% |
| 2023 Q3 | 21.84 Billion KRW | 1.93% |
| 2023 FY | 97.99 Billion KRW | -1.61% |
| 2023 Q1 | 31.16 Billion KRW | 13.42% |
| 2022 Q2 | 15.86 Billion KRW | -0.57% |
| 2022 Q4 | 27.47 Billion KRW | -31.79% |
| 2022 Q3 | 40.28 Billion KRW | 153.88% |
| 2022 FY | 99.59 Billion KRW | 86.17% |
| 2022 Q1 | 15.95 Billion KRW | 2.87% |
| 2021 Q2 | 13.64 Billion KRW | 28.69% |
| 2021 Q4 | 15.51 Billion KRW | 13.03% |
| 2021 Q1 | 10.6 Billion KRW | -45.09% |
| 2021 Q3 | 13.72 Billion KRW | 0.56% |
| 2021 FY | 53.49 Billion KRW | -41.73% |
| 2020 Q2 | 21.32 Billion KRW | -32.94% |
| 2020 FY | 91.79 Billion KRW | -19.49% |
| 2020 Q4 | 19.31 Billion KRW | -0.16% |
| 2020 Q3 | 19.34 Billion KRW | -9.3% |
| 2020 Q1 | 31.8 Billion KRW | 6.21% |
| 2019 Q3 | 29.39 Billion KRW | 5.82% |
| 2019 Q2 | 27.77 Billion KRW | 3.23% |
| 2019 Q1 | 26.9 Billion KRW | -2.39% |
| 2019 FY | 114.01 Billion KRW | 11.26% |
| 2019 Q4 | 29.94 Billion KRW | 1.88% |
| 2018 Q4 | 27.56 Billion KRW | 7.57% |
| 2018 Q3 | 25.62 Billion KRW | 1.14% |
| 2018 Q2 | 25.33 Billion KRW | 5.81% |
| 2018 Q1 | 23.94 Billion KRW | -20.52% |
| 2018 FY | 102.47 Billion KRW | -3.73% |
| 2017 Q1 | 23.46 Billion KRW | -26.4% |
| 2017 Q3 | 24.23 Billion KRW | -15.35% |
| 2017 Q4 | 30.12 Billion KRW | 24.35% |
| 2017 Q2 | 28.62 Billion KRW | 22.0% |
| 2017 FY | 106.44 Billion KRW | 152.03% |
| 2016 Q3 | 680.91 Million KRW | -80.54% |
| 2016 Q4 | 31.87 Billion KRW | 4581.22% |
| 2016 FY | 42.23 Billion KRW | 54.57% |
| 2016 Q2 | 3.49 Billion KRW | -43.36% |
| 2016 Q1 | 6.17 Billion KRW | -41.77% |
| 2015 Q1 | 4.31 Billion KRW | -65.01% |
| 2015 Q2 | 6.96 Billion KRW | 61.44% |
| 2015 Q4 | 10.61 Billion KRW | 95.01% |
| 2015 Q3 | 5.44 Billion KRW | -21.83% |
| 2015 FY | 27.32 Billion KRW | -25.26% |
| 2014 Q1 | 4.29 Billion KRW | 60.02% |
| 2014 Q2 | 8.8 Billion KRW | 105.09% |
| 2014 FY | 36.56 Billion KRW | 83.21% |
| 2014 Q3 | 11.14 Billion KRW | 26.65% |
| 2014 Q4 | 12.32 Billion KRW | 10.54% |
| 2013 Q2 | 3.78 Billion KRW | 134.04% |
| 2013 Q3 | 11.87 Billion KRW | 214.07% |
| 2013 Q4 | 2.68 Billion KRW | -77.42% |
| 2013 FY | 19.95 Billion KRW | 121.79% |
| 2013 Q1 | 1.61 Billion KRW | -49.12% |
| 2012 Q3 | 1.43 Billion KRW | 0.0% |
| 2012 FY | 8.99 Billion KRW | 0.0% |
| 2012 Q4 | 3.17 Billion KRW | 122.03% |
| Name | Revenue | Revenue Difference |
|---|